The US Food and Drug Administration appears to have concluded that Pfizer Inc.’s COVID vaccine should be authorized in children 5-11 even if a low incidence of infections mean the jabs create an excess number of hospitalizations for myocarditis relative to those prevented for the disease itself.
In briefing documents released ahead of the 26 October advisory committee review, FDA models several possible scenarios for the...







